Mimicking nature’s antibodies


Monoclonal antibodies (mAbs) synthesised in the laboratory aim to mimic natural antibodies which are produced by the body to selectively and specifically target pathogenic proteins or antigens in response to infection and neutralise them. When used as a therapeutic, mAbs employ the same approach to seek out and neutralise the target of interest.


Monoclonal antibodies have evolved over millions of years to seek out and neutralise potentially any target. Today, we continue to harness mAbs to build a broad portfolio of efficient and exquisitely specific biologics.

Herren Wu Senior Vice President, Antibody Discovery and Protein Engineering, R&D

Over the past three decades, mAbs have revolutionised the treatment of infectious diseases, cancer and chronic immunological diseases. Building on our long-standing heritage in this field from Cambridge Antibody Technology (CAT) and MedImmune, we harness our extensive antibody discovery and protein engineering platform to design mAbs for therapeutic applications. For example, we are able to optimise mAbs using our proprietary extended half-life technology which can extend the length of protection of the mAbs in the body. We are also using these platforms to design mAb fragments and bispecific mAbs, which can potentially offer wider therapeutic benefits unique to these modalities.

In addition to uncovering innovative ways to incorporate antibodies in cutting-edge therapies and diagnostics across oncology, we are developing novel mAbs that can target different drivers of inflammation in a number of respiratory and immunological conditions such as asthma and chronic obstructive pulmonary disease (COPD), as well as against infectious diseases such as respiratory syncytial virus (RSV) and COVID-19.1,2


References

1. Griffin MP, Yuan Y, Takas T, et al. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants [published correction appears in N Engl J Med. 2020 Jul 29;:]. N Engl J Med. 2020;383(5):415-425. doi:10.1056/NEJMoa1913556.

2. Zost SJ, Gilchuk P, Case JB, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2 [published online ahead of print, 2020 Jul 15]. Nature. 2020;10.1038/s41586-020-2548-6. doi:10.1038/s41586-020-2548-6.



Join us

If you believe in the power of what science can do, join us in our endeavour to push the boundaries of science to deliver life-changing medicines.


Collaborate with us

We know that however innovative our science, however effective our medicines and delivery, to achieve all we want to achieve, we cannot do it alone.